Resumen de acción 874
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, junto con sus filiales, se dedica a la investigación, desarrollo, fabricación y venta de medicamentos chinos patentados y occidentales, materias primas químicas, medicamentos naturales y biológicos y productos intermedios de materias primas químicas en la República Popular China y a escala internacional.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Recompensas
Análisis de riesgos
Competidores de Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | HK$20.95 |
| 52 Week High | HK$27.70 |
| 52 Week Low | HK$18.48 |
| Beta | 0.65 |
| 1 Month Change | 8.89% |
| 3 Month Change | 5.28% |
| 1 Year Change | -18.64% |
| 3 Year Change | 0% |
| 5 Year Change | -48.96% |
| Change since IPO | 1,463.43% |
Noticias y actualizaciones recientes
Recent updates
Do Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Earnings Warrant Your Attention?
Mar 08
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 33% Above Its Share Price
Feb 23Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has More To Do To Multiply In Value Going Forward
Feb 10Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?
Jan 25Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Popularity With Investors Is Under Threat From Overpricing
Jan 09With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case
Nov 28A Look At The Intrinsic Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Nov 15We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease
Oct 19Returns On Capital At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have Hit The Brakes
Oct 03Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Worth HK$21.9 Based On Its Intrinsic Value?
Aug 15Should You Be Adding Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) To Your Watchlist Today?
Aug 02Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Returns Have Hit A Wall
Jul 02Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Jun 01Here's Why Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Caught The Eye Of Investors
May 01The Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Aren't Growing
Mar 28Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt
Feb 23With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case
Jan 23Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Some Way To Go To Become A Multi-Bagger
Dec 24Estimating The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Nov 24Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Using Too Much Debt?
Nov 11Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?
Aug 02Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Paying Out A Larger Dividend Than Last Year
May 30Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 83% Above Its Share Price
Apr 29Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt
Apr 10We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease
Jan 09Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Rock Solid Balance Sheet
Oct 11Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Jul 12Why We Think Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) CEO Compensation Is Not Excessive At All
May 26How Does Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stand Up To These Simple Dividend Safety Checks?
Apr 30Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Shares Could Be 21% Above Their Intrinsic Value Estimate
Apr 08These 4 Measures Indicate That Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Using Debt Reasonably Well
Mar 25Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Mar 02Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Shareholders Have Enjoyed A 24% Share Price Gain
Feb 11
Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) A Smart Pick For Income Investors?
Jan 26Could The Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Ownership Structure Tell Us Something Useful?
Jan 06Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Pretty Healthy Balance Sheet
Dec 23Here's Why We Don't Think Guangzhou Baiyunshan Pharmaceutical Holdings's (HKG:874) Statutory Earnings Reflect Its Underlying Earnings Potential
Dec 09Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Nov 26Rentabilidad de los accionistas
| 874 | HK Healthcare | Mercado HK | |
|---|---|---|---|
| 7D | 2.9% | 7.9% | 5.5% |
| 1Y | -18.6% | -28.4% | -9.1% |
Rentabilidad vs. Industria: 874 superó al sector Hong Kong Healthcare , que obtuvo un rendimiento del -29.2% el año pasado.
Rentabilidad vs. Mercado: 874 obtuvo unos resultados inferiores a los del mercado Hong Kong, que fue del -10.9% el año pasado.
Volatilidad de los precios
| 874 volatility | |
|---|---|
| 874 Average Weekly Movement | 4.2% |
| Healthcare Industry Average Movement | 6.5% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 14.8% |
| 10% least volatile stocks in HK Market | 3.6% |
Precio estable de las acciones: 874 no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de 874 (4%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1997 | 28,048 | Hong Li | www.gybys.com.cn |
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, junto con sus filiales, se dedica a la investigación, desarrollo, fabricación y venta de medicamentos chinos patentados y occidentales, materias primas químicas, medicamentos naturales y biológicos y productos intermedios de materias primas químicas en la República Popular China y a escala internacional. La empresa opera a través de cuatro segmentos: Great Southern Medicine, Great Commerce, Great Health y Great Medical Care. También se dedica a la venta al por mayor y al por menor, a la importación y exportación de medicamentos occidentales y chinos, y de dispositivos médicos; y a la investigación y desarrollo, producción y venta de bebidas, alimentos, productos sanitarios y otros productos; y a la producción y venta de alimentos preenvasados, productos lácteos, etc., además de ofrecer infusiones, comprimidos, cápsulas, pastillas para chupar, gelatinas Guiling, etc. Además, la empresa invierte en la industria de la salud, como servicios médicos, gestión sanitaria, asistencia sanitaria, cuidado de ancianos, etc.; y presta servicios empresariales y de agencia de publicidad.
Resumen de fundamentos de Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited
| Estadísticas fundamentales de 874 | |
|---|---|
| Capitalización bursátil | HK$51.93b |
| Beneficios(TTM) | HK$4.43b |
| Ingresos (TTM) | HK$83.00b |
7.7x
Ratio precio-beneficio (PE)0.4x
Ratio precio-ventas (PS)¿Está 874 sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de 874 | |
|---|---|
| Ingresos | CN¥76.83b |
| Coste de los ingresos | CN¥62.65b |
| Beneficio bruto | CN¥14.19b |
| Otros gastos | CN¥10.08b |
| Beneficios | CN¥4.11b |
Últimos beneficios comunicados
Mar 31, 2024
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 2.53 |
| Margen bruto | 18.46% |
| Margen de beneficio neto | 5.34% |
| Ratio deuda/patrimonio | 34.2% |
¿Cómo se ha desempeñado 874 a largo plazo?
Ver rendimiento histórico y comparativa